Evidence map›Paper›PMID 35321237›Full record

ArticleDose-response : a publication of International Hormesis Society

Treatment of Early-Stage Alzheimer's Disease With CT Scans of the Brain: A Case Report.

Jerry M Cuttler, Maryélise S Lamet, Edward J Calabrese

Abstract read
In one paragraph

Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Low-Dose Non-Targeted Effects and Mitochondrial Control.International journal of molecular sciences · 2023
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jerry M CuttlerCuttler & Associates Inc, Vaughan, ON, CA.ORCID https://orcid.org/0000-0001-9532-9818
Maryélise S LametUniversity of Massachusetts, Amherst, MA, USA.
Edward J CalabreseNortheast Center, University of Massachusetts, Amherst, MA, USA.ORCID https://orcid.org/0000-0002-7659-412X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a patient in Massachusetts with early-stage Alzheimer's disease who was treated with low doses of ionizing radiation to the brain. He requested this treatment after reading about a patient with severe Alzheimer's in Michigan who improved remarkably after receiving 4 CT scans. After his first treatment in April 2016, mental clarity improved. His impaired conversation, reading, and sense of humor were restored, especially his virtuosic clarinet jazz-playing. However, executive function remained deficient. He requested a treatment every 2 weeks, but his neurologist denied this, fearing opposition to this treatment, a diagnostic procedure that used ionizing radiation. Limited recovery was observed after each CT scan, lasting from several weeks to months, depending on the endpoints/behavior and the periodicity. Despite the positive responses, the physician was reluctant to continue beyond 6 due to concerns about adverse effects and disapproval for prescribing them. The patient began hyperbaric oxygen therapy as an alternative. But after 43 treatments, no conclusive benefit was observed. The patient died in September 2020 at age 77. This experience suggests CT scans may have value in treating Alzheimer's patients and restoring, at least temporarily, important aspects of normal life activities. Such observations need testing and validation.

Indexed as

adaptive protection systemsalzheimer’s diseaseCT scan treatmentslow dose ionizing radiationoxidative DNA damagereactive oxygen species

Identifiers

PMID35321237
PMCPMC8935565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.